Subtotal $0.00
Shop Now
Zepbound sleep apnea approval came on December 20, 2024, when the FDA cleared Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and more physical activity. It was the first medicine approved for OSA. In the two 52-week SURMOUNT-OSA trials, breathing interruptions during sleep fell by roughly half on tirzepatide, versus almost no change on placebo, and people lost about 18% to 20% of their body weight. The approval covers obesity-related OSA only, and sleep specialists still see breathing machines, oral appliances and surgery as core options.
Peptide Labs does not sell Zepbound, Mounjaro or any prescription drug. This article summarizes the FDA label (revised August 2026), the published trials and guidance from sleep medicine groups. For the full list of reactions, see our guide to Zepbound side effects.
Key Takeaways
- The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024.
- SURMOUNT-OSA was two 52-week trials in 469 adults without type 2 diabetes, one with and one without CPAP-type therapy.
- The apnea-hypopnea index fell about 51% to 59% on tirzepatide versus about 3% on placebo.
- Up to half of people on tirzepatide reached remission or mild OSA without daytime sleepiness.
- The benefit is tied to weight loss, so it lasts only as long as the weight stays off.
- Mounjaro has the same ingredient but is not approved for sleep apnea; no other GLP-1 drug is.
What the Zepbound sleep apnea approval covers
Obstructive sleep apnea happens when the upper airway repeatedly narrows or closes during sleep, cutting airflow and oxygen. Its severity is measured with the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing episodes per hour. The trials enrolled adults with an AHI of 15 or more, which counts as moderate, and most had severe OSA, defined as 30 or more events an hour.
The label limits the sleep apnea use to adults with obesity, meaning a body mass index of 30 or more in the trials, and pairs it with diet and activity changes. Zepbound should not be combined with Mounjaro or any other GLP-1 medicine. The ingredient lowers weight, and excess weight is a major driver of airway collapse. The American Academy of Sleep Medicine (AASM) stresses that it helps only with sleep apnea related to obesity; many cases also stem from jaw and airway structure.
SURMOUNT-OSA: what the trials found
SURMOUNT-OSA, published in the New England Journal of Medicine in 2024 and funded by Eli Lilly, ran two randomized, double-blind trials for 52 weeks. Study 5 enrolled 234 adults who could not or would not use positive airway pressure (PAP) therapy such as CPAP. Study 6 enrolled 235 adults who were already using PAP; they paused the machine for a week before the final sleep study. People with type 2 diabetes were excluded, and everyone received diet and activity counseling. The table shows the main results from the August 2026 label.
| Result at week 52 | Study 5 (no PAP): placebo | Study 5: tirzepatide | Study 6 (on PAP): placebo | Study 6: tirzepatide |
|---|---|---|---|---|
| Change in breathing events per hour | -5.3 | -25.3 | -5.5 | -29.3 |
| Percent change in AHI | -3% | -50.7% | -2.5% | -58.7% |
| AHI cut by half or more | 19% | 61.2% | 23.3% | 72.4% |
| Remission or mild OSA without daytime sleepiness | 15.9% | 42.2% | 14.3% | 50.2% |
| Change in body weight | -1.6% | -17.7% | -2.3% | -19.6% |
Baseline AHI averaged about 50 events an hour, so the average person still had some sleep apnea at the end, even though a large minority reached remission or mild disease. Tirzepatide also lowered hypoxic burden (how much oxygen levels dropped), systolic blood pressure and a marker of inflammation, and people reported less sleep-related impairment. Results were consistent across age, sex, ethnicity, body mass index and baseline severity.
The label notes that the trials did not test whether, or when, people who were using PAP well could safely stop it. Side effects in the sleep apnea trials were similar to those in the weight trials, mostly nausea, diarrhea, vomiting and constipation, usually mild to moderate. Tiredness on these medicines has several possible causes, covered in our guide to fatigue on GLP-1 medicines.
Does tirzepatide sleep apnea therapy replace CPAP?
Not automatically. The National Heart, Lung, and Blood Institute calls a PAP machine the most common therapy for sleep apnea, and lists oral appliances, upper airway stimulation, surgery and healthy lifestyle changes as other options. The AASM welcomed the approval as a positive development but describes tirzepatide sleep apnea therapy as part of comprehensive care. Its main points:
- Zepbound works only for sleep apnea linked to obesity, not for cases driven mainly by airway anatomy.
- For some people, combining the medicine with another approach, such as PAP or an oral appliance, may be ideal.
- Weight loss has to be maintained over time to keep the sleep apnea benefit.
- Diagnosis and a care plan should come from a sleep physician, ideally at an accredited sleep center.
Do not stop or change PAP use on your own. A repeat sleep study, ordered by your clinician, is the usual way to see whether breathing has improved enough to change the plan.
GLP-1 and sleep apnea: how other medicines compare
Questions about GLP-1 and sleep apnea often lump these drugs together, but only Zepbound has the indication. Mounjaro contains the same ingredient yet is approved for type 2 diabetes only; our comparison of Mounjaro and Zepbound explains the differences. Semaglutide (Ozempic, Wegovy) is not approved for OSA.
Liraglutide, the ingredient in Saxenda, was tested in the 32-week SCALE Sleep Apnea trial, sponsored by Novo Nordisk, in 359 adults without diabetes. AHI fell by 12.2 events an hour versus 6.1 on placebo, with weight loss of 5.7% versus 1.6%. Saxenda did not receive a sleep apnea indication; see our liraglutide and semaglutide comparison for more. The bigger weight losses with tirzepatide fit with its larger AHI drop, which is consistent with weight being the main lever. For background on how the class works, read what GLP-1 medicines are.
Weight loss, regain and coverage
Because the effect on sleep apnea runs through weight loss, it fades if the weight comes back. Trials of GLP-1 medicines show weight tends to return after people stop, and that average losses level off over time; our overview of weight loss results in GLP-1 trials shows the curves.
On coverage, Medicare drug plans generally exclude medicines used only for weight loss. In January 2025, the Centers for Medicare and Medicaid Services confirmed that Part D plans can cover Zepbound when it is prescribed for obstructive sleep apnea, and that plans may require prior authorization. Coverage rules keep changing, so check the current details with your plan.
Sleep apnea and your eyes
Obstructive sleep apnea is also a recognized risk factor for a rare optic nerve stroke called NAION, which has been studied in people taking semaglutide. If you are weighing these medicines with a sleep apnea diagnosis, our article on Ozempic and vision explains what is and is not known.
Frequently Asked Questions
Is Zepbound FDA-approved for sleep apnea?
Yes. On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and more physical activity.
How well did Zepbound work for sleep apnea in SURMOUNT-OSA?
Breathing events per hour fell about 51% in people not using PAP and 59% in PAP users, versus about 3% on placebo. Up to half reached remission or mild OSA.
Can I stop using my CPAP machine on Zepbound?
Not without your sleep clinician. The trials did not test when PAP users could safely stop, and sleep experts see the medicine as part of comprehensive care.
Is Mounjaro approved for sleep apnea?
No. Mounjaro has the same ingredient, tirzepatide, but it is approved for type 2 diabetes. Only Zepbound carries the sleep apnea indication.
Do other GLP-1 drugs help sleep apnea?
Liraglutide reduced AHI modestly in a 32-week trial, but no GLP-1 medicine other than Zepbound is FDA-approved for sleep apnea.
Does Medicare cover Zepbound for sleep apnea?
In January 2025, CMS confirmed Part D plans can cover it for obstructive sleep apnea, possibly with prior authorization. Check your own plan’s current rules.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: Zepbound Side Effects: What the Latest Zepbound Label Reports, Mounjaro vs Zepbound: Same Tirzepatide, Different Approvals, GLP-1 for Weight Loss: What the Trials Actually Showed.